Last 20 Posts
- Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences
- Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
- Enzyvant Appoints Jeb Ledell as Chief Operating Officer
- Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
- Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting
- Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
- Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly
- Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802
- Enzyvant Receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Investigational Therapy RVT-802
- Rare Disease Day
- RARE in the Square
- Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome
- Roivant Sciences and Plexcera Therapeutics Announce the Formation of Enzyvant Sciences to Focus on the Treatment of Farber Disease
By Month
- December 2019 | November 2019 | October 2019 | June 2019 | April 2019 | February 2019 | July 2018 | September 2017 | April 2017 | February 2017 | January 2017 | July 2016 |